(c) 2024 PillSync.com

cyclobenzaprine hydrochloride tablet

INDICATIONS AND USAGE Cyclobenzaprine HCl tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine HCl tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine HCl tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.

kaiser foundation hospitals


6 years ago ROUND YELLOW TL 177 cyclobenzaprine hydrochloride tablet

ROUND YELLOW TL 177

6 years ago ROUND YELLOW TL 177 cyclobenzaprine hydrochloride tablet

TL 177 ROUND YELLOW

HOW SUPPLIED Cyclobenzaprine HCl Tablets, USP are available in the following strength and package sizes: 10 mg (yellow, round, film-coated, debossed with TL177 on one side and plain on the other side) Bottles of 30 (NDC 0179-0057-30) Bottles of 50 (NDC 0179-0057-50) Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature]. Manufactured by: Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA. Revised 02/07 Repackaged by: Kaiser Foundation Hospitals Livermore, CA 94551, USA.


More pills like ROUND TL 177












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site